Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 13:12:241.
doi: 10.1186/1471-2407-12-241.

Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors

Chia-Lin Hsu  1 , Kuan-Yu Chen, Jin-Yuan Shih, Chao-Chi Ho, Chih-Hsin Yang, Chong-Jen Yu, Pan-Chyr Yang
Affiliations

Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors

Chia-Lin Hsu et al. BMC Cancer. .

Abstract

Background: Lung cancer in young patients (less or equal to 45 years) is uncommon and has clinical characteristics different from that in older patients. We investigated the outcomes and prognostic factors of young patients with advanced non-small cell lung cancer (NSCLC).

Methods: From January 2000 to December 2009, we enrolled patients aged ≤45 years and diagnosed with stage IIIB or IV NSCLC. Their clinical data, including age, gender, performance status, histologic types, disease stages, laboratory data at diagnosis, treatment modalities, and survival were reviewed and analyzed. A Cox proportional hazard model was used to calculate the hazard ratio (HR) and its 95% confidence interval (CI).

Results: A total of 144 patients with advanced NSCLC were included. Female patients were more prevalent (n = 74, 51.4%). Adenocarcinoma was the most common histologic type (n = 119, 82.6%) in both genders (male, n = 54, 77.1%; female, n = 65, 87.8%). Epidermal growth factor receptor (EGFR) sequences were determined using tumor specimens from 58 patients, and 29 showed an EGFR mutation. No significant difference in median survival was found between patient groups with and without the EGFR mutation (798 vs. 708 days, p = 0.65). In multivariate analysis, male gender (HR, 1.70; 95% CI: 1.08-2.68), body mass index (BMI) less than 25 kg/m(2) (HR, 2.72; 95% CI: 1.39-5.30), stage IV disease (HR, 2.62; 95% CI: 1.50-4.57), and anemia (HR, 2.08; 95% CI: 1.15-3.77) were associated with a short survival time.

Conclusions: Low BMI, stage IV disease, anemia at diagnosis, and male gender were the negative prognostic factors for young patients with advanced NSCLC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incidence of non-small cell lung cancer among young patients between 2000 and 2009.
Figure 2
Figure 2
a. Proportion of adenocarcinoma in different age groups.b. Proportion of squamous cell carcinoma in different age groups.
Figure 3
Figure 3
a. Progression-free survival after chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in patients with theEGFRmutation.b. Progression-free survival after chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in patients without the EGFR mutation.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi: 10.3322/caac.20073. - DOI - PubMed
    1. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J. et al.Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–138. doi: 10.1016/S0140-6736(10)62231-3. - DOI - PMC - PubMed
    1. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773–783. doi: 10.1016/S1470-2045(07)70245-0. - DOI - PubMed
    1. Zhang J, Chen SF, Zhen Y, Xiang J, Wu C, Bao P, Luketich J, Hu H, Zhou X, Yao S. et al.Multicenter analysis of lung cancer patients younger than 45 years in Shanghai. Cancer. 2010;116(15):3656–3662. doi: 10.1002/cncr.25100. - DOI - PubMed
    1. Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol. 2010;5(1):23–28. doi: 10.1097/JTO.0b013e3181c41e8d. - DOI - PubMed